Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.

MLA

Barnell, Erica K., et al. “Distinct Clonal Identities of B-ALLs Arising after Lenolidomide Therapy for Multiple Myeloma.” Blood Advances, vol. 7, no. 2, Jan. 2023, pp. 236–45. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022007496.

APA

Barnell, E. K., Skidmore, Z. L., Newcomer, K. F., Chavez, M., Campbell, K. M., Cotto, K. C., Spies, N. C., Ruzinova, M. B., Wang, T., Abro, B., Kreisel, F., Parikh, B. A., Duncavage, E. J., Frater, J. L., Lee, Y.-S., Hassan, A., King, J. A., Kohnen, D. R., Fiala, M. A., … Wartman, L. D. (2023). Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Advances, 7(2), 236–245. https://doi.org/10.1182/bloodadvances.2022007496

Chicago

Barnell, Erica K, Zachary L Skidmore, Kenneth F Newcomer, Monique Chavez, Katie M Campbell, Kelsy C Cotto, Nicholas C Spies, et al. 2023. “Distinct Clonal Identities of B-ALLs Arising after Lenolidomide Therapy for Multiple Myeloma.” Blood Advances 7 (2): 236–45. doi:10.1182/bloodadvances.2022007496.